Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
May 10, 2017 7:30 AM EDTPositive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development
First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter
Continued Progress in the Commercialization of alfataliglicerase in Brazil
CARMIEL, Israel, May 10, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based... More
